The effects of curcumin on the prevention of atrial and ventricular arrhythmias and heart failure in patients with unstable angina: A randomized clinical trial

Document Type: Short communication

Authors

1 Department of cardiology, Faculty of medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Cardiovascular Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

4 Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

5 Department of Modern Sciences & Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

6 Department of Clinical Pharmacy, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

7 Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran

8 Department of Internal Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective: Inflammation along with oxidative stress has an important role in the pathophysiology of unstable angina which leads to acute myocardial infarction, arrhythmias and eventually heart failure. Curcumin has anti-inflammatory and anti-oxidant effects and thereby, it may reduce cardiovascular complications. This randomized controlled trial aimed to investigate the effects of curcumin on the prevention of atrial and ventricular arrhythmias and heart failure in patients with unstable angina.
Materials and Methods: Forty patients with unstable angina who met the trial inclusion and exclusion criteria, participated in this double-blind randomized clinical trial. The patients were randomized into two groups: curcumin (80 mg/day for 5days) and placebo (80 mg/day for 5days). Cardiac function was evaluated by two-dimensional echocardiography devices at baseline (immediately after hospitalization) and 5 days after the onset of the trial. Atrial and ventricular arrhythmias were recorded by Holter monitors in cardiology ward, Ghaem academic hospital, Mashhad, Iran. Progression to heart failure, myocardial infarction, and pulmonary and cardiopulmonary resuscitation events as well as mortality were recorded daily throughout the study.
Results: There were no significant differences between the two groups in atrial and ventricular arrhythmias (p=0.2), and other echocardiographic parameters (Ejection fraction, E, A, E/A ratio, Em, and pulmonary artery pressure) at baseline and five days after the start of the trial.
Conclusion:  Nanocurcumin administered at the dose of 80 mg/day for five days had no effect in the incidence of cardiovascular complications in patients with unstable angina.

Keywords

Main Subjects


Abe Y, Hashimoto S, Horie T. 1999. Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. Pharmacol Res, 39:41-47

Ahmadi M, Agah E, Nafissi S, Jaafari MRHarirchian MHSarraf PFaghihi-Kashani SHosseini SJGhoreishi AAghamollaii VHosseini MTafakhori A. 2018. Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial. Neurotherapeutics, 15:430-438.

Alwi I, Santoso T, Suyono S, Sutrisna B, Suyatna F, Kresn SB, Purwaningsih E. 2016. The Effects of Curcumin against the Inflammatory Response in Patients with Acute Coronary Syndrome. Cardiovasc Pharmacol: Open Access, 2016

Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm, 4:807-818

Chainani-Wu N. 2003. Safety and anti-inflammatory activity of curcumin: a component of tumeric (Curcuma longa). J Altern Complement Med, 9:161-168

Chen TH, Yang YC, Wang JC, Wang JJ. 2013. Curcumin Treatment Protects Against Renal Ischemia and Reperfusion Injury–Induced Cardiac Dysfunction and Myocardial Injury. Transplant Proc, 45: 546-549

Chuengsamarn S, Rattanamongkolgul S, Phonrat B, Tungtrongchitr R, Jirawatnotai S. 2014. Reduction of atherogenic risk in patients with type 2 diabetes by curcuminoid extract: a randomized controlled trial. J Nutr Biochem, 25: 144-150

Duan W, Yang Y, Yan J, Yu S, Liu J, Zhou J, Zhang J, Jin Z, Yi D. 2012. The effects of curcumin post-treatment against myocardial ischemia and reperfusion by activation of the JAK2/STAT3 signaling pathway. Basic Res Cardiol, 107: 1-12

Foussas S. 2015. Acute coronary syndromes. Hellenic J Cardiol, 56: 275-6

Gupta SC, Patchva S, Aggarwal BB. 2013. Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J, 15: 195-218

Hani U, Shivakumar HG. 2014. Solubility enhancement and delivery systems of curcumin a herbal medicine: a review. Curr Drug Deliv, 11: 792-804

Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. 2008. Curcumin: from ancient medicine to current clinical trials. Cell Mol Life Sci, 65: 1631-1652

Haverkate E, Thompson SG, Pyke SD, Gallimore JR, Group MBP. 1997. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet, 349: 462-466

Jobin C, Bradham CA, Russo MP, Juma BNarula ASBrenner DASartor RB. 1999. Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I-κB kinase activity. J Immunol, 163: 3474-3483

Kakkar V, Singh S, Singla D, Kaur IP. 2011. Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res, 55: 495-503

Kang B, Song Y, Kim KM, Choe Y, Hwang S, Kim TS. 1999a. Curcumin inhibits Th1 cytokine profile in CD4+ T cells by suppressing interleukin‐12 production in macrophages. Br J Pharmacol, 128:380-384

Kang BY, Chung SW, Chung W-J, Im S-Y, Hwang SY, Kim TS. 1999b. Inhibition of interleukin-12 production in lipopolysaccharide-activated macrophages by curcumin. Eur J Pharmacol, 384: 191-195

Khosravi A, Hashemi H, Farahani MM, Dolatkhah M, Rostami Z, Panahi Y. 2016. The Effects of Curcumin on Left Ventricular Function in Patients with Chronic Renal Failure. Arch Cardiovasc Imaging, 4:e38087.

Libby P. 2006. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr, 83: 456S-460S

Liuzzo G, Biasucci LM, Gallimore JR, Caligiuri GBuffon ARebuzzi AGPepys MBMaseri A. 1999. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol, 34: 1696-1703

Mason JC, Libby P. 2014. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J, 36: 482-489.

Mirzabeigi P, Mohammadpour AH, Salarifar M, Gholami K, Mojtahedzadeh M, Javadi MR. 2015. The Effect of Curcumin on some of Traditional and Non-traditional Cardiovascular Risk Factors: A Pilot Randomized, Double-blind, Placebo-controlled Trial. Iran J Pharm Res, 14:479

Nabavi SF, Daglia M, Moghaddam AH, Habtemariam S, Nabavi SM. 2014. Curcumin and liver disease: from chemistry to medicine. Compr Rev Food Sci Food Saf, 13:62-77

Naik SR, Thakare VN, Patil SR. 2011. Protective effect of curcumin on experimentally induced inflammation, hepatotoxicity and cardiotoxicity in rats: evidence of its antioxidant property. Exp Toxicol Pathol, 63:419-431

Nordstokke DW, Zumbo BD, Cairns SL, Saklofske DH. 2011. The operating characteristics of the nonparametric Levene test for equal variances with assessment and evaluation data. PARE, 16: 1-8

Rahimi HR, Mohammadpour AH, Dastani M,   Jaafari MR,Abnous KH,Ghayour Mobarhan M, Kazemi OskueeR. 2016a. The effect of nano-curcumin on HbA1c, fasting blood glucose, and lipid profile in diabetic subjects: a randomized clinical trial. Avicenna J Phytomed, 6: 567

Rahimi HR, Nedaeinia R, Sepehri Shamloo A, Nikdoust S, Kazemi Oskuee R. 2016b. Novel delivery system for natural products: Nano-curcumin formulations. Avicenna J Phytomed, 6:383-398

Rahimi HR, Oskuee RK. 2014. Curcumin from Traditional Iranian Medicine to Molecular Medicine. Razavi Int J Med, 2

Sahebkar A, Mohammadi A, Atabati A, Rahiman STavallaie SIranshahi MAkhlaghi SFerns GAGhayour-Mobarhan M. 2013. Curcuminoids Modulate Pro‐Oxidant–Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and Oxidized LDL in Obese Individuals. Phytother Res, 27: 1883-1888

Santel T, Pflug G, Hemdan NYA, Schäfer A, Hollenbach M, Buchold M, Hintersdorf A, Lindner J, Otto A, Bigl M, Oerlecke l, Hutschenreuter A, Sack U, Birkenmeier G. 2008. Curcumin inhibits glyoxalase 1—a possible link to its anti-inflammatory and anti-tumor activity. PLoS One, 3:e3508

Schoonderwoerd BA, Smit MD, Pen L, Van Gelder IC. 2008. New risk factors for atrial fibrillation: causes of ‘not-so-lone atrial fibrillation’. Europace, 10:668-673

Shishodia S, Singh T, Chaturvedi MM. 2007. Modulation of transcription factors by curcumin the molecular targets and therapeutic uses of curcumin in health and disease. Springer, p 127-148

Srivastava R, Dikshit M, Srimal R, Dhawan B. 1985. Anti-thrombotic effect of curcumin. Thromb Res, 40:413-417

Tsimikas S, I Miller Y. 2011. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des, 17:27-37

Whang W, Shimbo D, Kronish IM, Duval WL, Julien H, Lyer P, Burg M, Davidson K. 2010. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]). Am J Cardiol, 106: 1104-1107

Wongcharoen W, Phrommintikul A. 2009. The protective role of curcumin in cardiovascular diseases. Int J Cardiol, 133: 145-151

Yamashita H, Shimada K, Seki E, Mokuno H, Daida H. 2003. Concentrations of interleukins, interferon, and C-reactive protein in stable and unstable angina pectoris. Am J Cardiol, 91:133-136

Yeghiazarians Y, Braunstein JB, Askari A, Stone PH. 2000. Unstable angina pectoris. N Engl J Med, 342: 101-114